Episode
Outsmarting Resistance with Rhythm
- Podcast
- The Bio Report
- Published
- Mar 18, 2026
- Duration seconds
- 2299
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/outsmarting-resistance-with-rhythm/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/outsmarting-resistance-with-rhythm.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Pancreatic cancer remains one of oncology’s deadliest diagnoses, with standard treatments often offering only transient tumor shrinkage at the cost of grueling side effects and rapid resistance. Immuneering is using transcriptomic and informatics tools to design a MEK inhibitor dosed in intense daily pulses rather than continuously. This approach aims to restore a more normal signaling rhythm in healthy cells while repeatedly ambushing tumors. Ben Zeskind, CEO of Immuneering, discusses how the company is using its informatics-driven dosing regimen to re-engineer targeted cancer therapy so it extends survival, delays resistance, and is better tolerated.